ATE498392T1 - Ophthalmische emulsionen mit einem immunsuppressiven mittel - Google Patents

Ophthalmische emulsionen mit einem immunsuppressiven mittel

Info

Publication number
ATE498392T1
ATE498392T1 AT08102553T AT08102553T ATE498392T1 AT E498392 T1 ATE498392 T1 AT E498392T1 AT 08102553 T AT08102553 T AT 08102553T AT 08102553 T AT08102553 T AT 08102553T AT E498392 T1 ATE498392 T1 AT E498392T1
Authority
AT
Austria
Prior art keywords
emulsions containing
ophthalmic emulsions
immunosupressive agent
agent
immunosupressive
Prior art date
Application number
AT08102553T
Other languages
English (en)
Inventor
Betty Philips
Severine Bague
Laura Rabinovich-Guilatt
Gregory Lambert
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE498392(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Application granted granted Critical
Publication of ATE498392T1 publication Critical patent/ATE498392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
AT08102553T 2004-11-09 2005-10-10 Ophthalmische emulsionen mit einem immunsuppressiven mittel ATE498392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292645A EP1655021B1 (de) 2004-11-09 2004-11-09 Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US10/991,346 US8298568B2 (en) 2004-11-09 2004-11-18 Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential

Publications (1)

Publication Number Publication Date
ATE498392T1 true ATE498392T1 (de) 2011-03-15

Family

ID=34931510

Family Applications (5)

Application Number Title Priority Date Filing Date
AT04292645T ATE412400T1 (de) 2004-11-09 2004-11-09 Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
AT05800012T ATE415942T1 (de) 2004-11-09 2005-10-10 Prostaglandine enthaltende ophthalmische emulsionen
AT05795930T ATE418964T1 (de) 2004-11-09 2005-10-10 Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential
AT05802097T ATE412401T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsion mit einem immunosuppressiven mittel
AT08102553T ATE498392T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsionen mit einem immunsuppressiven mittel

Family Applications Before (4)

Application Number Title Priority Date Filing Date
AT04292645T ATE412400T1 (de) 2004-11-09 2004-11-09 Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
AT05800012T ATE415942T1 (de) 2004-11-09 2005-10-10 Prostaglandine enthaltende ophthalmische emulsionen
AT05795930T ATE418964T1 (de) 2004-11-09 2005-10-10 Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential
AT05802097T ATE412401T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsion mit einem immunosuppressiven mittel

Country Status (13)

Country Link
US (5) US8298568B2 (de)
EP (1) EP1655021B1 (de)
JP (3) JP5587936B2 (de)
CN (3) CN101014317A (de)
AT (5) ATE412400T1 (de)
DE (5) DE602004017477D1 (de)
DK (1) DK1809237T3 (de)
ES (4) ES2314354T3 (de)
IL (3) IL181446A (de)
MX (2) MX2007003045A (de)
NZ (1) NZ554929A (de)
PT (2) PT1809238E (de)
ZA (1) ZA200703751B (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232320B2 (en) 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
EP1655021B1 (de) * 2004-11-09 2008-10-29 Novagali Pharma SA Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US20070054834A1 (en) * 2005-04-11 2007-03-08 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
CA2618974C (en) * 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
EP2001439A2 (de) * 2006-03-07 2008-12-17 Novavax, Inc. Nanoemulsionen von schlecht löslichen pharmazeutischen aktivbestandteilen und herstellungsverfahren dafür
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
AU2014201978B2 (en) * 2006-07-28 2016-03-10 Santen Sas Compositions containing quaternary ammonium compounds
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
EP1891939B1 (de) * 2006-07-28 2013-09-11 Novagali Pharma S.A. Zusamensetzungen die quaternäre Ammonium Verbindungen enthalten
US20080026013A1 (en) * 2006-07-28 2008-01-31 Laura Rabinovich-Guilatt Compositions containing quaternary ammonium compounds
EP2444829A1 (de) 2006-09-14 2012-04-25 Carl Zeiss SMT GmbH Optische Elementeinheit und Verfahren zum Stützen eines optischen Elements
EP1938801A1 (de) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
EP1985298A1 (de) 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090018057A1 (en) * 2007-07-09 2009-01-15 Gregory Lambert OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
EA201070483A1 (ru) * 2007-10-16 2010-10-29 Сан Фарма Адвансед Ресьёрч Компани Лимитед Новые офтальмологические композиции
WO2009063081A2 (en) * 2007-11-14 2009-05-22 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.
US7834172B2 (en) * 2007-11-14 2010-11-16 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC
EP2077105A1 (de) * 2008-01-02 2009-07-08 Novagali Pharma SA Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität
EP2077104A1 (de) * 2008-01-02 2009-07-08 Novagali Pharma SA Mizellare Zusammensetzungen mit ophtalmischen Anwendungen
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
JP5645381B2 (ja) * 2008-09-04 2014-12-24 参天製薬株式会社 １５，１５−ジフルオロプロスタグランジンＦ２α誘導体を有効成分として含有する毛髪成長促進剤
WO2010026239A1 (en) * 2008-09-05 2010-03-11 Ceva Sante Animale Sa Composition comprising chitosan for ocular administration of vaccine(s) to avians
EP2376089B1 (de) 2008-11-17 2018-03-14 The Regents of the University of Michigan Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
EP2228057A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20130011354A1 (en) * 2009-11-09 2013-01-10 Allergan, Inc. Compositions For Enhancing Hair Growth
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
KR20130051476A (ko) * 2010-07-15 2013-05-20 코린시언 아프샐믹 인코포레이티드 안과용 약물 전달
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
CA2824317C (en) 2011-01-19 2014-12-16 Terakine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
HUE037660T2 (hu) 2011-01-26 2018-09-28 Allergan Inc Androgén készítmény szembetegség kezelésére
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
RU2641963C2 (ru) 2011-11-15 2018-01-23 Аллерган, Инк. Взвеси циклоспорина а формы 2
US20130123194A1 (en) 2011-11-15 2013-05-16 Allergan, Inc. Autoclavable suspensions of cyclosporin a form 2
US9205150B2 (en) 2011-12-05 2015-12-08 Incept, Llc Medical organogel processes and compositions
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
EP2821467B1 (de) * 2012-02-24 2018-02-14 Fain-Biomedical Inc. Verwendung eines schmierfähigkeits-regulierungsmittels für siliconoberflächen
WO2014032026A1 (en) 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2014039012A1 (en) * 2012-09-06 2014-03-13 Nanyang Technological University Hyaluronic acid-based drug delivery systems
KR101651448B1 (ko) 2012-11-21 2016-08-26 토포카인 쎄라퓨틱스, 인코포레이티드 체지방을 국소적으로 증가시키는 방법 및 조성물
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
ES2930433T3 (es) 2013-03-05 2022-12-12 Univ Pittsburgh Commonwealth Sys Higher Education Hidrogel termosensible que contiene micropartículas de polímero para la administración ocular no invasiva de fármaco
CN105073112B (zh) * 2013-03-13 2017-12-29 参天制药株式会社 睑板腺功能障碍的治疗剂
US20140275261A1 (en) * 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
RU2513597C1 (ru) * 2013-04-17 2014-04-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения воспалительных состояний переднего отрезка глаза
NO2753788T3 (de) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
RU2016136430A (ru) 2014-02-11 2018-03-15 Др. Редди'С Лабораторис Лтд. Парентеральные композиции целекоксиба
KR20160146669A (ko) * 2014-02-14 2016-12-21 징준 후앙 나노에멀젼 전달 시스템의 조성물
EP3154531A1 (de) * 2014-06-13 2017-04-19 Sanofi Nanokapselformulierung aus pharmazeutischen wirkstoffen
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
CN107249678B (zh) * 2014-12-19 2021-02-19 凯敏工业公司 使用离子电渗法进行生物活性分子的眼内递送
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
EP3253372B8 (de) * 2015-02-06 2022-06-22 Woodstock Sterile Solutions, Inc. Herstellung einer öl-in-wasser-emulsion für polymerstabilisierte pharmazeutische formulierungen
CN106176600A (zh) * 2015-05-07 2016-12-07 上海现代药物制剂工程研究中心有限公司 一种前列地尔冻干微乳剂、原料组合物及其制备方法
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
PL3373976T3 (pl) 2015-11-10 2024-06-24 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego i ich zastosowanie
MX2018010395A (es) 2016-02-29 2018-11-29 Sun Pharma Global Fze Formulaciones topicas que contienen cliclosporina y usos de las mismas.
JP6906899B2 (ja) * 2016-03-30 2021-07-21 小林製薬株式会社 乳化組成物
WO2017192773A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
WO2017192774A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
KR102122887B1 (ko) 2016-05-03 2020-06-16 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
EP4624054A3 (de) 2016-05-03 2025-11-19 Pneuma Respiratory, Inc. Verfahren zur erzeugung und abgabe von tröpfchen an das lungensystem unter verwendung einer tröpfchenabgabevorrichtung
WO2017192782A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
RS58292B1 (sr) * 2016-07-07 2019-03-29 Salvat Lab Sa Oftalmološka kompozicija sa ricinusovim uljem i srednjim lancem triglicerida
CN106782348A (zh) * 2017-01-04 2017-05-31 深圳市华星光电技术有限公司 一种led背光驱动电路及液晶显示器
AU2018205253B2 (en) 2017-01-06 2022-01-13 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP4223335A3 (de) 2017-05-19 2023-11-08 Pneuma Respiratory, Inc. Vorrichtung zur ausgabe von trockenpulver und verfahren zur verwendung
EP3630042A4 (de) * 2017-05-30 2021-06-23 Eximore Ltd. Zusammensetzungen und verfahren zur behandlung von trockenem auge mittels freisetzung von antibiotischem macrolid
US11938056B2 (en) 2017-06-10 2024-03-26 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
EP3697481B1 (de) 2017-10-17 2024-05-22 Pneuma Respiratory, Inc. Nasale arzneimittelabgabevorrichtung und verwendungsverfahren
WO2019089573A1 (en) 2017-10-30 2019-05-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
WO2019162951A1 (en) * 2018-02-26 2019-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
EP3817743A4 (de) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
CN109010268B (zh) * 2018-09-28 2020-07-10 湖北远大天天明制药有限公司 一种提高氯霉素稳定性的眼用组合物及其制备方法
WO2020102810A1 (en) 2018-11-16 2020-05-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive gel eye drop for ocular delivery of cysteamine
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN110237233B (zh) * 2019-07-30 2021-01-15 沈阳兴齐眼药股份有限公司 一种含有环孢素的眼用药物组合物、其制备方法及用途
WO2021113637A1 (en) 2019-12-04 2021-06-10 Restore Vision, Llc. Ophthalmic formulations for the treatment of presbyopia
CA3164288A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
US20230210771A1 (en) * 2020-06-10 2023-07-06 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
WO2022271848A1 (en) 2021-06-22 2022-12-29 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
WO2023004813A1 (zh) 2021-07-30 2023-02-02 京东方科技集团股份有限公司 像素电路、驱动方法和显示装置
CN113577024B (zh) * 2021-08-20 2023-05-05 山西利普达医药科技有限公司 一种眼用组合物及其制备方法和应用
CN116407499B (zh) * 2021-12-29 2024-10-25 辅必成（上海）医药科技有限公司 一种他克莫司眼用乳剂及其制备方法
US20260033533A1 (en) 2022-07-18 2026-02-05 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method
WO2024208433A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
WO2024208434A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion
WO2025030169A2 (en) * 2023-08-03 2025-02-06 Arcum Vision Inc. Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses
CN120960148B (zh) * 2025-09-15 2026-04-10 安徽辰旭视光科技有限公司 一种用于治疗免疫性干眼症的眼用纳米乳制剂及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPH0818989B2 (ja) 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
JP2602964B2 (ja) 1989-10-16 1997-04-23 裕 水島 プロスタグランジン類縁体およびその脂肪乳剤
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
CA2142103C (en) * 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JP3551977B2 (ja) * 1993-04-08 2004-08-11 ライオン株式会社 安定なビタミンａ類及びビタミンｅ類可溶化点眼剤
EP0631770B1 (de) * 1993-06-25 1998-07-22 Alcon Cusi, S.A. Neue Verwendung von polymeren Membranen zum Ausgeben von pharmazeutischen Lösungen, die quarternäre, als Konserviermittel dienende Ammoniumverbindungen enthalten und entsprechender Dosierbehälter
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5739105A (en) * 1994-06-01 1998-04-14 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
ES2094688B1 (es) * 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5767153A (en) * 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
DE69807281T2 (de) 1997-05-14 2003-04-17 Mitsubishi Chemical Corp., Tokio/Tokyo Difluprednat enthaltende Zusammensetzungen
JP3410364B2 (ja) * 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US20020136771A1 (en) * 1998-12-31 2002-09-26 Amitee Cosmetics, Inc. Stabilized ascorbic acid composition
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
EP1418903A2 (de) * 2001-04-23 2004-05-19 The Board of Regents of the University of Texas System Prostanoide verstärken die okulare penetration von arzneimitteln
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
US6872705B2 (en) * 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
IL161588A0 (en) * 2001-11-01 2004-09-27 Yissum Res Dev Co Method and composition for dry eye treatment
KR100446960B1 (ko) 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
AU2003262268A1 (en) 2002-08-23 2004-04-30 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
CA2707067C (en) 2002-09-09 2013-07-16 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US20040115234A1 (en) * 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP4361294B2 (ja) * 2003-02-25 2009-11-11 ロート製薬株式会社 ケトチフェン含有組成物
JP4694773B2 (ja) * 2003-06-06 2011-06-08 ロート製薬株式会社 粘膜適用液状組成物
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP5382972B2 (ja) * 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物
US20050175651A1 (en) * 2004-01-09 2005-08-11 L'oreal Aqueous dispersion of nanocapsules with an oily core
ATE439123T1 (de) 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
JP4999304B2 (ja) * 2004-09-27 2012-08-15 ロート製薬株式会社 ヒアルロン酸又はその塩を含有する粘膜適用組成物
KR101319772B1 (ko) * 2004-11-09 2013-10-23 노바갈리 파르마 에스 에이 면역 억제제를 포함하는 안과용 유제
EP1655021B1 (de) * 2004-11-09 2008-10-29 Novagali Pharma SA Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
US20090170944A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Ophthalmic micellar compositions with enhanced stability
KR20160123400A (ko) * 2008-05-28 2016-10-25 알콘 리서치, 리미티드 자기보존 에멀젼
EP2228058A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2228057A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen

Also Published As

Publication number Publication date
CN101056615B (zh) 2011-05-11
US20080107738A1 (en) 2008-05-08
US20080268020A1 (en) 2008-10-30
HK1107938A1 (en) 2008-04-25
ES2319129T3 (es) 2009-05-04
CN101014317A (zh) 2007-08-08
ES2320574T3 (es) 2009-05-25
DE602005011480D1 (de) 2009-01-15
ATE412400T1 (de) 2008-11-15
EP1655021B1 (de) 2008-10-29
DE602005010733D1 (de) 2008-12-11
US8298568B2 (en) 2012-10-30
DK1809237T3 (da) 2009-05-04
ES2317319T3 (es) 2009-04-16
JP5587936B2 (ja) 2014-09-10
DE602004017477D1 (de) 2008-12-11
CN101056615A (zh) 2007-10-17
JP2014088450A (ja) 2014-05-15
HK1112411A1 (en) 2008-09-05
US20070248645A1 (en) 2007-10-25
ZA200703751B (en) 2008-08-27
US20060100288A1 (en) 2006-05-11
PT1809238E (pt) 2009-02-09
IL190497A0 (en) 2008-11-03
DE602005012136D1 (de) 2009-02-12
EP1655021A1 (de) 2006-05-10
CN103356481A (zh) 2013-10-23
MX2007005545A (es) 2007-07-05
ES2314354T3 (es) 2009-03-16
JP5773941B2 (ja) 2015-09-02
IL182897A0 (en) 2007-08-19
DE602005026464D1 (de) 2011-03-31
CN103356481B (zh) 2017-11-28
ATE415942T1 (de) 2008-12-15
MX2007003045A (es) 2007-08-02
IL181446A0 (en) 2007-07-04
US20090028955A1 (en) 2009-01-29
JP5894202B2 (ja) 2016-03-23
ATE412401T1 (de) 2008-11-15
IL190497A (en) 2012-01-31
ATE418964T1 (de) 2009-01-15
US8298569B2 (en) 2012-10-30
US8372434B2 (en) 2013-02-12
IL182897A (en) 2010-12-30
JP2012162549A (ja) 2012-08-30
IL181446A (en) 2010-06-16
US8273362B2 (en) 2012-09-25
JP2012149102A (ja) 2012-08-09
PT1809237E (pt) 2009-04-09
NZ554929A (en) 2010-09-30

Similar Documents

Publication Publication Date Title
ATE412401T1 (de) Ophthalmische emulsion mit einem immunosuppressiven mittel
WO2006050837A3 (en) Ophthalmic emulsions containing an immunosuppressive agent
Froelich et al. Microemulsion-based media in nose-to-brain drug delivery
BRPI0411306A (pt) composições farmacêuticas compreendendo compostos ativos de vitamina d
BRPI0506983A (pt) composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
BR0214679A (pt) Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
ES2134850T3 (es) Emulsiones farmaceuticas o cosmeticas aceite en agua de particulas cargadas positivamente.
EA200401252A1 (ru) Микрочастицы лекарственных веществ
BR0100424A (pt) Nanoemulsão óleo-em-água que contém lipìdios anfìfilos e um polìmero não iÈnico, composição cosmética de uso tópico, suas utilizações, processo de tratamento não terapêutico e processo para espessar as nanoemulsões óleo-em -água
WO2004026231A3 (en) Formulation for lipophilic agents
DE69926862D1 (de) Kosmetische oder dermo-pharmazeutische zusammensetzung in form von hydrophoben perlen und herstellungsverfahren
EP1543811A4 (de) L-in-wasser-emulsionszusammensetzung mit teilchen
WO2005072709A3 (en) Formulations for poorly soluble drugs
DE602004022523D1 (de) Verwendung von Emulsionen zur intra- und periocularen Injection
WO2005027822A3 (en) Stabilized formulations of phosphatidylserine
CN108430446A (zh) 包含负电荷物质的微尘防尘用组合物
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
DE60310605D1 (de) Nanoteilchen zur verabreichung von wirkstoffen, verfahren zur herstellung dieser teilchen und diese enthaltende zusammensetzung
Salamah et al. Development and characterization of in situ gelling nasal cilostazol spanlastics
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
EP1782824A3 (de) Pharmazeutische Zusammensetzungen, die Diaminooxidase enthalten
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
DE602004015876D1 (de) Lichtschutzformulierung in der Form einer Öl-Wasser-Nanoemulsion, deren Herstellung und Verwendung in der Kosmetik und in der Dermatologie
Muzib et al. Development of a Brain-Targeted Donepezil Nanoemulsion via Intranasal Route with Pharmacodynamic Study for Alzheimer’s Management

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties